Yosra Bouraoui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yosra Bouraoui has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Banasr
Department of Legal Medicine, Hospital of Charles Nicolle Tunis, Tunisia
1 shared publication - Ali Horchani
Department of Urology, La Rabta Hospital, Tunis, Tunisia
1 shared publication - Awatef Ben Jemaa
Unit IMEC-Immunology Microbiology Environmental and Carcinogenesis, Faculty of Science of Bizerte, University of Carthage, Tunisia; Department of Biology, Faculty of Science of Gafsa, University of Gafsa, Tunisia
1 shared publication - Latifa Ouertani
Department of Anathomopathology, Hospital of Menzel Bourguiba, Tunisia
1 shared publication Mar Royuela
Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain
1 shared publicationMongia Achour
Unit Immuno-Microbio Environmental and Carcinogenesis (IMEC), Faculty of Sciences of Bizerte, Carthage University, Jarzouna, Tunisia
1 shared publication
Latest Publications
- Open Access
- 26 October 2017
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 34 (3) , 125-133
Immune profiling of human prostate epithelial cells determined by expression of p38/TRAF‐6/ERK MAP kinases pathways
The aim of the present work was to study the immune profiling of prostate epithelial cells by the expression of ASK‐1/p38 and Raf‐1/ERK MAP Kinases signaling pathways mediated by TRAF‐6. Immunohistochemical and Western blot analyses for TRAF‐6, ASK‐1, MEK‐6, p38, Raf‐1, MEK‐1, ERK‐1, ERK‐2 and PSA were carried out in 5 samples of normal prostate gland, 24 samples of BPH and 19 samples of PC. Immunoreaction to TRAF‐6 was found in the cytoplasm of epithelial cells of BPH and tumor cells of PC samples. For patients with the profile (TRAF‐6+), optical densities revealed a weak immunoexpression of ASK‐1 in PC compared to BPH patients. Whereas, immunoexpression to Raf‐1 was higher in PC than in BPH. According to the expression of ASK‐1 and Raf‐1, two main profiles were identified: (TRAF‐6+, ASK‐1+, Raf‐1+) and (TRAF‐6+, ASK‐1+, RAF‐1−) in both BPH and PC. In addition, ASK‐1/p38 axis expression was increased in BPH. Raf‐1/ERK signaling pathway was increased in PC samples. On the other hand, representing of individual signaling protein expression enclosing each of p38 and ERK MAP Kinases according to TRAF‐6+ showed a qualitative behavior of ASK61/p38 and Raf‐1/ERK signaling pathways and a dynamic expression of PSA associated with immune and inflammatory process. These findings suggest that prostate epithelial cell could able an immune and inflammatory setting.
- 26 October 2017
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 34 (3) , 125-133
Open AccessImmune profiling of human prostate epithelial cells determined by expression of p38/TRAF‐6/ERK MAP kinases pathways
The aim of the present work was to study the immune profiling of prostate epithelial cells by the expression of ASK‐1/p38 and Raf‐1/ERK MAP Kinases signaling pathways mediated by TRAF‐6. Immunohistochemical and Western blot analyses for TRAF‐6, ASK‐1, MEK‐6, p38, Raf‐1, MEK‐1, ERK‐1, ERK‐2 and PSA were carried out in 5 samples of normal prostate gland, 24 samples of BPH and 19 samples of PC. Immunoreaction to TRAF‐6 was found in the cytoplasm of epithelial cells of BPH and tumor cells of PC samples. For patients with the profile (TRAF‐6+), optical densities revealed a weak immunoexpression of ASK‐1 in PC compared to BPH patients. Whereas, immunoexpression to Raf‐1 was higher in PC than in BPH. According to the expression of ASK‐1 and Raf‐1, two main profiles were identified: (TRAF‐6+, ASK‐1+, Raf‐1+) and (TRAF‐6+, ASK‐1+, RAF‐1−) in both BPH and PC. In addition, ASK‐1/p38 axis expression was increased in BPH. Raf‐1/ERK signaling pathway was increased in PC samples. On the other hand, representing of individual signaling protein expression enclosing each of p38 and ERK MAP Kinases according to TRAF‐6+ showed a qualitative behavior of ASK61/p38 and Raf‐1/ERK signaling pathways and a dynamic expression of PSA associated with immune and inflammatory process. These findings suggest that prostate epithelial cell could able an immune and inflammatory setting.
- Open Access
- 28 December 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 171
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
Background: The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. Methods: The study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression, respectively. Results: In our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18 and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues (16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA. Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+) expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity. Conclusion: These data suggest that these markers are regulated differentially and the difference in their expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies the significance of their investigation together in normal and pathologic prostate tissues.
- 28 December 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 171
Open AccessCo-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
Background: The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. Methods: The study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression, respectively. Results: In our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18 and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues (16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA. Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+) expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity. Conclusion: These data suggest that these markers are regulated differentially and the difference in their expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies the significance of their investigation together in normal and pathologic prostate tissues.